Go­ing af­ter Hunt­ing­ton's dis­ease again, ex-Te­va R&D chief gets some cash for Prile­ni­a's re­newed ef­forts

Even while serv­ing as the glob­al R&D head for Te­va sev­er­al years ago, Michael Hay­den had high hopes for a drug known as pri­do­pi­dine. But he wasn’t al­ways on the right track.

Re­searchers orig­i­nal­ly be­lieved the drug, now the lead as­set of Dutch start­up Prile­nia Ther­a­peu­tics, was a dopamine mod­u­la­tor. While pri­do­pi­dine was in the midst of a Phase II study for Hunt­ing­ton’s dis­ease at Te­va, how­ev­er, Hay­den re­al­ized his as­sump­tions about the com­pound were off-base.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER